Boston Business Journal: Life sciences firm Locust Walk’s plans for its $175M SPAC
LOCUST WALK NEWS Boston Business Journal: Life sciences firm Locust Walk’s plans for its $175M SPAC Geoff Meyerson co-founded Locust […]
LOCUST WALK NEWS Boston Business Journal: Life sciences firm Locust Walk’s plans for its $175M SPAC Geoff Meyerson co-founded Locust […]
Doubling Down Following up on our recent white paper, Biopharma’s COVID Capital Comeback, here is a look at the greatest risk
Biopharma’s COVID Capital Comeback What a difference a few months can make – especially during a pandemic. Heading into 2020,
The Unexpected IPO Boom for Biopharma in Q2 SUBSCRIBE TO OUR INSIGHTS Linkedin Twitter Youtube Instagram CATEGORIES News Locust Walk
Panel Recording on 6.11: Accessing Capital in the Time of COVID CATEGORIES Asian Capabilities Capital Raising Commercial Assessment Locust Walk
The impact on partnerships for public biotech companies CATEGORIES Asian Capabilities Capital Raising Commercial Assessment Locust Walk Institute Market Trends
Brian Coleman of Locust Walk to Moderate Panel at BioEquity Europe: Drawing Your Financing Roadmap CATEGORIES Asian Capabilities Capital Raising
Finding the invisible, how to meet Family Offices CATEGORIES Asian Capabilities Capital Raising Commercial Assessment Locust Walk Institute Market Trends
Navigating the MedTech Fundraising Environment CATEGORIES Asian Capabilities Capital Raising Commercial Assessment Locust Walk Institute Market Trends Multitrack Process Negotiation
Why is Family Office money so hard to find for life science companies? CATEGORIES Asian Capabilities Capital Raising Commercial Assessment